Ofatumumab

Ofatumumab is a fully human anti-CD20 monoclonal antibody that induces antibody-dependent cell-mediated cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC) in CD20-expressing B lymphocytes. Ofatumumab has strong lytic activity against CD20-positive B lymphocytes and eliminates CD20-positive tumor cells through ADCC and CDC. Ofatumumab is particularly effective against drug-resistant cells with low CD20 expression and can be applied to the research of chronic lymphocytic leukemia (CLL) [1][2][3].

Product Specifications

CAS Number

[679818-59-8]

Product Name Alternative

GSK1841157; OMB-157

UNSPSC

12352203

Target

CD20

Type

Inhibitory Antibodies

Related Pathways

Immunology/Inflammation

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/ofatumumab.html

Purity

99.00

Solubility

H2O

Smiles

[Ofatumumab]

Molecular Weight

(145.94 kDa)

References & Citations

[1]Barth MJ, et al. Ofatumumab Exhibits Enhanced In Vitro and In Vivo Activity Compared to Rituximab in Preclinical Models of Mantle Cell Lymphoma. Clin Cancer Res. 2015 Oct 1;21 (19) :4391-7.|[2]Barth MJ, et al. Ofatumumab demonstrates activity against rituximab-sensitive and -resistant cell lines, lymphoma xenografts and primary tumour cells from patients with B-cell lymphoma. Br J Haematol. 2012 Feb;156 (4) :490-8.|[3]Sanford M, et al. Ofatumumab. Drugs. 2010;70 (8) :1013-1019.